Alzheimer’s drug donanemab helps most when taken at earliest disease stage, study finds

An experimental drug can slow progression of Alzheimer’s disease in those who start taking it when the disease is still in its early stages. The drug, a monoclonal antibody called donanemab, does not improve symptoms. But among people who started taking it at the earliest stages of Alzheimer’s, 47% had no disease progression on some measures after one year, compared with 29% who took a placebo.

Nature 619, 682-683 (2023)

doi: https://doi.org/10.1038/d41586-023-02321-1

Related Articles

• Alzheimer’s drug donanemab: what promising trial means for treatments

• Controversial Alzheimer’s drug approval could affect other diseases

• Could drugs prevent Alzheimer’s? These trials aim to find out

• More Alzheimer’s drugs head for FDA review: what scientists are watching

Subjects

Latest on:

• Neurodegeneration

• 

  Cell-type signatures of Alzheimer’s disease shared across population groups

  Article 15 JUL 26

• 

  Dementia risk in middle-aged people linked to a blood protein

  Research Highlight 26 JUN 26

• 

  The brain region that could provide a cognitive ‘reservoir’ in old age

  Research Highlight 17 JUN 26